Zanolimumab
Zanolimumab is an investigational human monoclonal antibody that acts as an immunosuppressant. It binds to CD4, a molecule on certain immune cells. It was studied as a potential treatment for rheumatoid arthritis, psoriasis, melanoma, and cutaneous or peripheral T‑cell lymphomas. However, its development was stopped and all clinical trials were terminated, so it is not approved or available as a medicine.
This page was last edited on 3 February 2026, at 06:31 (CET).